Skip to content

Talphera, Inc. TLPH Fair Value Adjustment Of Warrants

Fair Value Adjustment Of Warrants at other companies

Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$89K+96.1%

Other financials

Income statement

See full
Revenue--100%
Gross profit-$1.9M-52.7%
Operating income-$3.9M-35.4%
Net income-$2.6M+1.4%
EPS (diluted)-$0.10+37.5%

Balance sheet

See full
Cash & equivalents$3.8M-29.0%
Total debt$3.4M-79.7%
Total equity$18.5M+230%
Total assets$30.2M+101%

Cash flow

See full
Operating cash flow-$3.4M+2.0%
CapEx-
Free cash flow-$2.3M+42.9%

Valuation

See full
Market cap$53.46M+516%
P/S53,456.6×+53,135×

Profitability

See full
Gross margin-127.7%-136pp
Operating margin-1,451,600%-1,507,145pp
Net margin-1,425,300%-1,471,200pp
FCF margin-5,116.7%-6,779pp

Returns & leverage

See full
Return on equity-118.4%+15.4pp
Debt / equity0.2×
Current ratio5.3×+2.2×

Where this comes from

Reported directly by Talphera, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.

The official record: Talphera, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Talphera, Inc.'s fair value adjustment of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Talphera, Inc.'s fair value adjustment of warrants?
Talphera, Inc. (TLPH) reported fair value adjustment of warrants of -$1.22M in Q1 2026.
How has Talphera, Inc.'s fair value adjustment of warrants changed year-over-year?
Talphera, Inc.'s fair value adjustment of warrants decreased by 575.7% year-over-year, from -$181K to -$1.22M.
What is the long-term trend for Talphera, Inc.'s fair value adjustment of warrants?
Over 2 years (2023 to 2025), Talphera, Inc.'s fair value adjustment of warrants has grown at a -52.0% compound annual growth rate (CAGR), from -$5.72M to $1.32M.
What does fair value adjustment of warrants mean?
This metric represents the periodic change in the estimated fair value of outstanding warrant liabilities as required by accounting standards. Because these adjustments are non-cash in nature, they reflect market-based valuation fluctuations rather than operational performance. Investors track this to isolate the impact of derivative revaluations on net income.